Autopsy report · NCT01464034
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Cause of deathSlow enrollment
“Lack of enrollment”
Life of this trial
- Ran for about 8 years 8 months before it stopped.
- 136 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Criterium, Inc.
- Sponsor type
- Industry
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib; Pomalidomide; Dexamethasone
- Participants
- 136
- Sites
- 9
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.